1
|
Kacsoh DB, Diaz MJ, Gozlan EC, Sahoo A, Song JJ, Yeagley M, Chobrutskiy A, Chobrutskiy BI, Blanck G. Blood-based T cell receptor anti-viral CDR3s are associated with worse overall survival for neuroblastoma. J Cancer Res Clin Oncol 2023; 149:12047-12056. [PMID: 37421457 DOI: 10.1007/s00432-023-05059-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Accepted: 06/28/2023] [Indexed: 07/10/2023]
Abstract
With the advent of large collections of adaptive immune receptor recombination reads representing cancer, there is the opportunity to further investigate the adaptive immune response to viruses in the cancer setting. This is a particularly important goal due to longstanding but still not well-resolved questions about viral etiologies in cancer and viral infections as comorbidities. In this report, we assessed the T cell receptor complementarity determining region-3 (CDR3) amino acid (AA) sequences, for blood-sourced TCRs from neuroblastoma (NBL) cases, for exact AA sequence matches to previously identified anti-viral TCR CDR3 AA sequences. Results indicated the presence of anti-viral TCR CDR3 AA sequences in the NBL blood samples highly significantly correlated with worse overall survival. Furthermore, the TCR CDR3 AA sequences demonstrating chemical complementarity to many cytomegalovirus antigens represented cases with a worse outcome, including cases where such CDR3s were obtained from tumor samples. Overall, these results indicate a significant need for, and provide a novel strategy for assessing viral infection complications in NBL patients.
Collapse
Affiliation(s)
- Dorottya B Kacsoh
- College of Medicine, University of Central Florida, Orlando, FL, 32827, USA
| | - Michael J Diaz
- Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, 12901 Bruce B. Downs Bd. MDC7, Tampa, FL, 33612, USA
| | - Etienne C Gozlan
- Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, 12901 Bruce B. Downs Bd. MDC7, Tampa, FL, 33612, USA
| | - Arpan Sahoo
- Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, 12901 Bruce B. Downs Bd. MDC7, Tampa, FL, 33612, USA
| | - Joanna J Song
- Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, 12901 Bruce B. Downs Bd. MDC7, Tampa, FL, 33612, USA
| | - Michelle Yeagley
- University of Pittsburgh Medical Center, Pittsburgh, PA, 15261, USA
| | - Andrea Chobrutskiy
- Department of Pediatrics, Oregon Health and Science University, Portland, OR, 97239, USA
| | - Boris I Chobrutskiy
- Department of Internal Medicine, Oregon Health and Science University Hospital, Portland, OR, 97239, USA
| | - George Blanck
- Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, 12901 Bruce B. Downs Bd. MDC7, Tampa, FL, 33612, USA.
- Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
| |
Collapse
|
3
|
Bartek J, Fornara O, Merchut-Maya JM, Maya-Mendoza A, Rahbar A, Stragliotto G, Broholm H, Svensson M, Sehested A, Söderberg Naucler C, Bartek J, Bartkova J. Replication stress, DNA damage signalling, and cytomegalovirus infection in human medulloblastomas. Mol Oncol 2017; 11:945-964. [PMID: 28383788 PMCID: PMC5537913 DOI: 10.1002/1878-0261.12061] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2017] [Revised: 03/04/2017] [Accepted: 03/13/2017] [Indexed: 12/22/2022] Open
Abstract
Medulloblastomas are the most common, and often fatal, paediatric brain tumours that feature high genomic instability, frequent infection by human cytomegalovirus (HCMV) and resistance to radiation and chemotherapy. The causes of the pronounced chromosomal instability and its potential links with HCMV infection and/or resistance to genotoxic therapies remain largely unknown. To address these issues, here we have combined immunohistochemical analysis of a series of 25 paediatric medulloblastomas, complemented by medulloblastoma cell culture models including experimental HCMV infection. Using eight established immunohistochemical markers to assess the status of the DDR machinery, we found pronounced endogenous DNA damage signalling (γH2AX marker) and robust constitutive activation of both the ATM‐Chk2 and ATR‐Chk1 DNA damage checkpoint kinase cascades, yet unexpectedly modest p53 tumour suppressor activation, across our medulloblastoma cohort. Most tumours showed high proliferation (Ki67 marker), variable oxidative DNA damage (8‐oxoguanine lesions) and formation of 53BP1 nuclear ‘bodies’, the latter indicating (along with ATR‐Chk1 signalling) endogenous replication stress. The bulk of the clinical specimens also showed expression of HCMV immediate early and late proteins, in comparative analyses using three immunohistochemical protocols. Cell culture experiments validated the chronic endogenous replication stress in medulloblastoma cell lines and showed sharply differential, intriguing responses of normal cells and medulloblastoma cells to HCMV infection, including differential subcellular mislocalization and enhancement of replication stress‐related 53BP1 body formation, the latter in cell‐non‐autonomous manner. Overall, our results strongly indicate that in human medulloblastomas, the DDR checkpoint barrier is widely activated, at least in part due to replication stress. Furthermore, we propose that unorthodox p53 defects other than mutations may allow high proliferation despite the ongoing checkpoint signalling and that the highly prevalent HCMV may impact the medulloblastoma host cell replication stress and DNA repair. Collectively, the scenario we report here likely fuels genomic instability and evolution of medulloblastoma resistance to standard‐of‐care genotoxic treatments.
Collapse
Affiliation(s)
- Jiri Bartek
- Department of Medicine, Unit of Microbial Pathogenesis, Karolinska Institutet, Stockholm, Sweden.,Danish Cancer Society Research Center, Copenhagen, Denmark.,Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden.,Department of Neurosurgery, Copenhagen University Hospital Rigshospitalet, Denmark
| | - Olesja Fornara
- Department of Medicine, Unit of Microbial Pathogenesis, Karolinska Institutet, Stockholm, Sweden
| | | | | | - Afshar Rahbar
- Department of Medicine, Unit of Microbial Pathogenesis, Karolinska Institutet, Stockholm, Sweden
| | - Giuseppe Stragliotto
- Department of Medicine, Unit of Microbial Pathogenesis, Karolinska Institutet, Stockholm, Sweden
| | - Helle Broholm
- Department of Pathology, Copenhagen University Hospital Rigshospitalet, Denmark
| | - Mikael Svensson
- Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden
| | - Astrid Sehested
- Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Denmark
| | | | - Jiri Bartek
- Danish Cancer Society Research Center, Copenhagen, Denmark.,Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Science for Life Laboratory, Karolinska Institute, Stockholm, Sweden
| | - Jirina Bartkova
- Danish Cancer Society Research Center, Copenhagen, Denmark.,Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Science for Life Laboratory, Karolinska Institute, Stockholm, Sweden
| |
Collapse
|
4
|
Baumgarten P, Michaelis M, Rothweiler F, Starzetz T, Rabenau HF, Berger A, Jennewein L, Braczynski AK, Franz K, Seifert V, Steinbach JP, Allwinn R, Mittelbronn M, Cinatl J. Human cytomegalovirus infection in tumor cells of the nervous system is not detectable with standardized pathologico-virological diagnostics. Neuro Oncol 2014; 16:1469-77. [PMID: 25155358 PMCID: PMC4201076 DOI: 10.1093/neuonc/nou167] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2014] [Accepted: 07/13/2014] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND Experimental findings have suggested that human cytomegalovirus (HCMV) infection of tumor cells may exert oncomodulatory effects that enhance tumor malignancy. However, controversial findings have been published on the presence of HCMV in malignant tumors. Here, we present the first study that systematically investigates HCMV infection in human nervous system tumors by highly sensitive immunohistochemistry in correlation with the HCMV serostatus of the patients. METHODS Immunohistochemical and quantitative PCR-based methods to detect different HCMV antigens and genomic HCMV DNA were optimized prior to the investigation of pathological samples. Moreover, the pathological results were matched with the HCMV serostatus of the patients. RESULTS HCMV immediate-early, late, and pp65 antigens could be detected in single cells from HCMV strain Hi91-infected UKF-NB-4 neuroblastoma cells after 1:1024 dilution with noninfected UKF-NB-4 cells. Genomic HCMV DNA could be detected in copy numbers as low as 430 copies/mL. However, we did not detect HCMV in tumors from a cohort of 123 glioblastoma, medulloblastoma, or neuroblastoma patients. Notably, we detected nonspecifically positive staining in tumor tissues of HCMV seropositive and seronegative glioblastoma patients. The HCMV serostatus of 67 glioblastoma patients matched the general epidemiological prevalence data for Western countries (72% of female and 57% of male glioblastoma patients were HCMV seropositive). Median survival was not significantly different in HCMV seropositive versus seronegative glioblastoma patients. CONCLUSIONS The prevalence of HCMV-infected tumor cells may be much lower than previously reported based on highly sensitive detection methods.
Collapse
Affiliation(s)
- Peter Baumgarten
- Neurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.)
| | - Martin Michaelis
- Neurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.)
| | - Florian Rothweiler
- Neurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.)
| | - Tatjana Starzetz
- Neurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.)
| | - Holger F Rabenau
- Neurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.)
| | - Annemarie Berger
- Neurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.)
| | - Lukas Jennewein
- Neurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.)
| | - Anne K Braczynski
- Neurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.)
| | - Kea Franz
- Neurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.)
| | - Volker Seifert
- Neurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.)
| | - Joachim P Steinbach
- Neurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.)
| | - Regina Allwinn
- Neurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.)
| | - Michel Mittelbronn
- Neurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.)
| | - Jindrich Cinatl
- Neurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.)
| |
Collapse
|